GemVax & KAEL Completes Patient Enrollment for P2 Clinical Trial into GV1001

Mar 13, 2019 | Alzheimer, Korea, Korean Clinical Trials

Alzheimer Disease

Korea Biomedical Review reports that Korea-based GemVex & KAEL has reported it has completed patient registration for the phase II clinical trial of GV1001 to treat patients who have Alzheimer’s disease.

GV1001 is a peptide derived from a hTERT (Human Telomerase reverse transcriptase) consisting of 16 amino acids.  The enzyme telomerase maintains the length of telomere located at the end of chromosomes, and the treatment has anti-inflammation, anti-oxidation cellular protective effects, as well as anti-cancer effect.  The completion of registration comes after the company started conducting the phase 2 clinical trials at 12 clinic sites, including Hanyang University Guri Hospital, evaluating the safety and therapeutic efficacy of GV1001 in patients with moderate to severe Alzheimer’s disease in August 2017. The trial is the only clinical trial that targets patients with moderate to severe Alzheimer’s disease, among 15 Alzheimer’s disease clinical trials currently conducted in Korea.


Pin It on Pinterest